Nemolizumab ( DrugBank: Nemolizumab )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
51	全身性強皮症	2

51. 全身性強皮症

---

臨床試験数 : 525 /  薬物数 : 565 - (DrugBank : 148) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2031210481	20/04/2022	12/12/2021	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Systemic Sclerosis	Systemic Sclerosis	Nemolizumab will be administered subcutaneously	Nishiura Tomoyuki	NULL	Recruiting	>= 20age old	<= 70age old	Both	8	Phase 2	Japan
2	NCT05214794 (ClinicalTrials.gov)	April 20, 2022	17/1/2022	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis	An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis	Systemic Sclerosis	Drug: nemolizumab	Maruho Co., Ltd.	NULL	Recruiting	20 Years	70 Years	All	8	Phase 2	Japan